Earlier this summer, CLL Society joins other patient advocacy organizations in calling for a number of patient protections for Medicare Part D’s “Smoothing” program that started in 2025. Meant to allow patients to spread their out-of-pocket costs across the plan year and avoid one large payment with one costly prescription drug, the program can make a meaningful difference for many of our patients. However, we must ensure patients have a clear understanding of qualifications and exclusions, plans must have a clear appeals process if disqualified, and financial hardship exceptions must be clear. More details can be found in the attached letter.
